Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796400 | 1.00 | USP2 (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL1184732 | 1.00 | USP2 (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| Water SCHEMBL16056602 | 0.98 | MAPT (0.43) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL28078175 | 0.89 | NR1H2 (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL28078177 | 0.89 | NR1H2 (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL27567585 | 0.89 | USP2 (0.45) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL19201225 | 0.88 | HPGD (0.49) | USP2SMN1; SMN2MAPTMAPK1HPGD | |
| SCHEMBL2392691 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL30289051 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 | |
| SCHEMBL14959559 | 0.87 | HPGD (0.44) | USP2SMN1; SMN2MAPTNR1H2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716807-A | Synthesis process of (R) -1-N-BOC-3-piperazine methyl formate | 苏利制药科技江阴有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12600710-B2 | Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260098039-A1 | SOLID FORMS OF COMPOUND I OR SALTS THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2026-04-09 | — | — | US | disclosed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4705299-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | Rayzebio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| US-5620987-A | Amino acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5554756-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | USP2 4487/4885SMN1; SMN2 2680/4885MAPT 4058/4885 |
| US-12600710-B2 | Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors | BCL9, BCL9L, BCL3 | USP2 2511/4885SMN1; SMN2 4672/4885MAPT 4550/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | USP2 4551/4885SMN1; SMN2 2759/4885MAPT 4121/4885 |
| US-20260098039-A1 | SOLID FORMS OF COMPOUND I OR SALTS THEREOF | LDHA, SLC25A11, LDHB | USP2 3227/4885SMN1; SMN2 1207/4885MAPT 381/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | USP2 2703/4885SMN1; SMN2 2592/4885MAPT 3767/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | USP2 3521/4885SMN1; SMN2 1255/4885MAPT 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.